Abstract
We analyzed a nationwide post-marketing surveillance study of mizoribine (MZR) for rheumatoid arthritis (RA) to assess the efficacy and safety of MZR in terms of renal function using chronic kidney disease (CKD) stage and to assess the effect of MZR on renal function using estimated glomerular filtration rates (eGFR).
Of the 1,805 registered patients in the study, 417 patients treated with MZR were assessed using eGFR.
The improvement rate in ACR20 after 6 months for all 417 cases was 29.2%, and the rate for each sub-group based on CKD stage did not significantly differ. Adverse reactions to the MZR treatment were seen in 13.7% of the 417 cases, and the incidence of adverse reactions did not significantly differ between CKD stage sub-groups.
Deterioration of renal function was not seen in any of the CKD stage sub-groups. However, significant improvement was observed for patients in stage 3 as eGFRs at the start and at six months were 50.2±7.0mL/min/1.73m² and 60.2±17.9mL/min/1.73m², respectively.
These results suggest that MZR can effectively be used for RA patients in CKD stage 3.
